Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial
Circulation · 2024
DOI: 10.1161/circulationaha.124.069903 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, 2024. Verfasst von William F McIntyre und 15 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Research Institute, McMaster University, Hamilton, Canada (W.M., S.F.L., A.B., J.H., S.C.). Hauptthemen laut MEDLINE: Atrial Fibrillation, Pyrazoles, Stroke, Pyridones. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Themen: Schlaganfall
Abstract (Originalsprache)
BACKGROUND: In the ARTESiA trial (Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation), apixaban, compared with aspirin, reduced stroke or systemic embolism in patients with device-detected subclinical atrial fibrillation (SCAF). Clinical guidelines recommend considering SCAF episode duration when deciding whether to prescribe oral anticoagulation for this population. METHODS: We performed a retrospective cohort study in ARTESiA. Using Cox regression adjusted for CHA 2 DS 2 -VASc score and treatment allocation (apixaban or aspirin), we assessed frequency of SCAF episodes and duration of the longest SCAF episode in the 6 months before randomization as predictors of stroke risk and of apixaban treatment effect. RESULTS: Among 3986 patients with complete baseline SCAF data, 703 (17.6%) had no SCAF episode ≥6 minutes in the 6 months before enrollment. Among 3283 patients (82.4%) with ≥1 episode of SCAF ≥6 minutes in the 6 months before enrollment, 2542 (77.4%) had up to 5 episodes, and 741 (22.6%) had ≥6 episodes. The longest episode lasted
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Population Health Research Institute, McMaster University, Hamilton, Canada (W.M., S.F.L., A.B., J.H., S.C.).
- Vancouver Stroke Program, University of British Columbia, Canada (T.F.).
- Working Group on Cardiovascular Research (M.A.).
- Hospital Universitario La Luz, Madrid, Spain (J.B.-M.).
- University of Modena and Reggio Emilia, Modena, Italy (G.B.).
- Aarhus University Hospital, Denmark (J.N.).
ORCID-Profile: Jeff S Healey, Stuart J Connolly, Mu Yang, Shun Fu Lee, Thalia S Field, Marco Alings, J Benezet-Mazuecos, Giuseppe Boriani, J Cosedis Nielsen, Francesco Pergolini, Taya V Glotzer, Christopher B Granger, Renato D Lopes
Zitieren
APA
McIntyre, W. F., Benz, A. P., Healey, J. S., Connolly, S. J., Yang, M., Lee, S. F., Field, T. S., Alings, M., Benezet-Mazuecos, J., Boriani, G., Nielsen, J. C., Gold, M. R., Pergolini, F., Glotzer, T. V., Granger, C. B., & Lopes, R. D. (2024). Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial. Circulation. https://doi.org/10.1161/circulationaha.124.069903
Vancouver
McIntyre WF, Benz AP, Healey JS, Connolly SJ, Yang M, Lee SF, et al. Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial. Circulation. 2024. doi:10.1161/circulationaha.124.069903
BibTeX
@article{McIntyre2024,
author = {McIntyre, William F and Benz, Alexander P and Healey, Jeff S and Connolly, Stuart J and Yang, Mu and Lee, Shun Fu and Field, Thalia S and Alings, Marco and Benezet-Mazuecos, J and Boriani, Giuseppe and Nielsen, J Cosedis and Gold, Michael R and Pergolini, Francesco and Glotzer, Taya V and Granger, Christopher B and Lopes, Renato D},
title = {Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial},
journal = {Circulation},
year = {2024},
doi = {10.1161/circulationaha.124.069903}
}
EUVIMED